Aurigene will be attending the New York Bio’s Annual Meeting, scheduled to be held on May 10-11, 2017 at New York City. For more details about the event, please click here.
CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism
Aurigene will be attending 2017 MassBio Annual Meeting, scheduled to be held on March 30-31, 2017 at Boston, Massachusetts. For more details about the conference, please click here
Aurigene will be attending 2017 American Academy of Dermatology Annual Meeting, scheduled to be held on March 03-07, 2017 at Orlando, Florida. For more details about the conference, please click
Advances in New Drug Discovery & Development Feb 2-4, 2017, Ahmedabad, India Scientists and R & D professionals from across the globe will be at arms reach when they gather
J.P Morgan Annual Healthcare Conference continues to be one of the life science industry’s largest conferences of the year. It brings thousands of investors and executives from around the world
Aurigene will be attending AACR-NCI-EORTC 2016, scheduled to be held on November 29- December 02, 2016 at Munich, Germany. For more details about the conference, please click here
Aurigene will be attending BIO-EUROPE 2016, scheduled to be held on November 07-09, 2016 at Cologne, Germany. For more details about the conference, please click here
Aurigene will be attending Pennsylvania BIO’s annual signature event Life Sciences Future, scheduled to be held on Oct 25-26, 2016 at Philadelphia, PA. For more details about the conference, please click here
Aurigene a discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases, announced today the nomination of the development candidate and exercising of the option
